TechnoPhage initiates Phase I/IIa study of TP-102 bacteriophage treatment for diabetic foot infections
TechnoPhage announced the beginning of Phase I/IIa study (REVERSE) of TP-102, a phage therapy candidate for the treatment of Diabetic Foot Infections (DFI). The first-in-human study is designed to evaluate the safety and tolerability of TP-102 in subjects with both...
Manuel Garrido will attend Phage Futures Congress 2021
TechnoPhage’s Production Specialist, Manuel Garrido, will attend the Phage Futures Virtual Congress 2021. Manuel will participate in the panel session hosted by Adam Ostrowski, Technical Application Specialist at Cellexus. The remaining panellists include Jonathan...